Firm censured

TruScreen, the cervical cancer test developer which is listed on the NZX Alternative Market, has been publicly censured by the New Zealand Markets Disciplinary Tribunal for having just one New Zealand resident director for 18 business days, falling short of the requirement for at least two, after former director Tim Preston withdrew his nomination on the eve of the company’s annual meeting in September. The stock market’s disciplinary tribunal said TruScreen had only one director who was ordinarily resident in New Zealand following its September 21 annual meeting. TruScreen and NZX reached a settlement over the breach, involving a public censure by the tribunal and requiring TruScreen to pay tribunal costs, if any, and $1800 of costs to NZX. cumulative rise over the previous two weeks. Views towards future economic conditions slipped 0.7 per cent — its second straight weekly fall. worldwide. Amazon’s headcount grew rapidly last year, up 66 per cent from 2016. Amazon says it hired 130,000 people last year. children thrive. “Fake news, racism, sexism, terrorists spreading messages of hate, toxic content directed at children — parts of the Internet we have ended up with is a million miles from where we thought it would take us. It is in the digital media industry’s interest to listen and act on this.” — BusinessDesk Bahrain and Egypt that since last summer has forced it to fly longer routes through Turkey and Iran has hit the company’s bottom line, but not its expansion plans.